Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor

Phase 3

Completed

Conditions: Central Nervous System Tumor
Brain Tumor

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Radiation: radiation therapy

First Posted Date: 2004-06-11

Last Posted Date: 2018-09-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 24

Registration Number: NCT00085098

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Driscoll Children's Hospital, Corpus Christi, Texas, United States

and more 103 locations

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

Phase 2

Completed

Conditions: Central Nervous System Tumor, Pediatric

Interventions: Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: cytarabine
Drug: dexrazoxane hydrochloride
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: leucovorin calcium
Drug: methotrexate
Drug: temozolomide
Drug: therapeutic hydrocortisone
Drug: vincristine sulfate
Radiation: radiation therapy
Drug: Dactinomycin

First Posted Date: 2004-06-11

Last Posted Date: 2015-12-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00084838

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States

and more 9 locations

Surgery Plus Radiation Therapy With or Without Chemotherapy in Treating Children With Primitive Neuroectodermal Tumors of the CNS

Phase 3

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-06-09

Last Posted Date: 2013-12-04

Lead Sponsor: Societe Internationale d'Oncologie Pediatrique

Target Recruit Count: 230

Registration Number: NCT00003859

Locations: 🇬🇧
St. James's Hospital, Leeds, England, United Kingdom

Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer

Phase 2

Terminated

Conditions: Cervical Cancer
Ovarian Cancer

First Posted Date: 2004-06-09

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00002478

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 44 locations